TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT04973605: A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417as Monotherapy, in Combination With Dexamethasone, Dexamethasone/Carfilzomib, Dexamethasone/Daratumumab, and Dexame

Sponsor: BeOne Medicines · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 246 pts

Competing Trials Overlap

9 Active Trials

Excess Burn Exposure

$471,240

Rescue Site Savings

+$314,160

Unlock Full NCT04973605 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT04973605 Rescue Dossier →